PROGRAF APPROVAL

Prograf Now Approved for Prophylaxis Use in Heart Transplantation Across EuropeTOKYO and LONDON, April 21 /PRNewswire/ -- Astellas Pharma Inc. ( Astellas ; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that the European Commission has approved the immunosuppressant Prograf(R) (generic name: tacrolimus) for the prophylaxis use of transplant rejection in recipients of heart transplants in all EU countries(x). This outcome is a result of the European Commission's decision to harmonise the summary of product characteristics (SPC) of Prograf(R) across all EU member states. The immunosuppressive calcineurin inhibitor Prograf(R) is already indicated for the prophylaxis of organ rejection in kidney and liver transplant patients in EU countries.